Table of Contents  
Year : 2015  |  Volume : 6  |  Issue : 3  |  Page : 185-187  

International conference on harmonization of technical requirements for registration of pharmaceuticals for human use

Section Editor, JPP, Government Medical College, Amritsar, Punjab, India

Date of Web Publication4-Aug-2015

Correspondence Address:
Jatinder Singh
Section Editor, JPP, Government Medical College, Amritsar, Punjab
Login to access the Email id

Source of Support: Nil., Conflict of Interest: There are no conflicts of interest.

DOI: 10.4103/0976-500X.162004

Rights and Permissions

How to cite this article:
Singh J. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. J Pharmacol Pharmacother 2015;6:185-7

How to cite this URL:
Singh J. International conference on harmonization of technical requirements for registration of pharmaceuticals for human use. J Pharmacol Pharmacother [serial online] 2015 [cited 2021 Oct 24];6:185-7. Available from:

The pharmaceutical industry is one of the largest global businesses. It is also associated with steady innovation in terms of development of new drugs and has to keep abreast of the constantly changing regulatory and technical aspects associated with the process. In addition, there are a number of ethical and economic issues ranging from safety, quality, profits, patent rights, and protection that need to be considered.

Following famous cases such as the Nazi’s experiments on concentration camp prisoners in WWII and the Tuskegee syphilis study (1932–1972), agreements for the conduct of clinical research were created. These included the 1947 Nuremberg code, the 1964 Declaration of Helsinki, and the 1979 Belmont Report. These led to the realization that it was important to have an independent evaluation of medicinal products before they are allowed on the market. This was followed by introduction of new regulations and guidelines for reporting and evaluating the data on safety, quality, and efficacy of new medicinal products in almost every country. The variance in technical requirements from country to country made it necessary to duplicate many time consuming and expensive test procedures in order to release new medicines in the international market. This resultant increase in cost of research and health care made it necessary to rationalize and harmonize regulation so as to make safe and efficacious new treatments available to patients in the minimum amount of time.

The idea of harmonization of regulatory requirements was decided by Europe, Japan, and the United States. This idea gave rise to the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) in 1990 at a WHO conference on Drug Regulatory Authorities in Paris.

The formalization of the concept of harmonization led to immediate benefits to the regulatory authorities and the pharmaceutical industry. The ICH recommendations helped in preventing duplication of clinical trials and minimizing the use of animal testing at the same time taking care of safety and effectiveness. The recommendations also streamlined the regulatory process for new drug applications, thereby reducing the development times and optimizing resources for drug development. The ICH has since then entered the electronic era with a stress on paperless application process and sharing of real time information among the stakeholders.

The website of the ICH ( is the portal for the organizations’ activities and links information for various meetings, policies, trainings, and news.

The history of the organization and the algorithm of the harmonization process are explained in the introductory link. The Steering Committee that governs the activities of ICH consists of representatives from the founders (European Union, European Federation of Pharmaceutical Industries and Associations, Ministry of Health Labour and Welfare, Japan, Japan Pharmaceuticals Manufacturer’s Association, Food and Drug Administration, USA, Pharmaceutical Research and Manufacturers of America, Swissmedic and Health Canada). The WHO participates as an observer and International Federation of Pharmaceutical Manufacturers and Associations as a non voting member.

Work Products link to downloadable Quality, Safety, Efficacy, and Multidisciplinary guidelines. The Quality guidelines include topics relevant to good manufacturing practices (GMP) and cover diverse topics related to stability studies, analytical validation, pharmacopoeias, and quality risk management amongst others. The Safety guidelines relate to genotoxicity, reproductive toxicity, and other safety evaluations. Efficacy guidelines are comprehensive and relate to the design, conduct, safety and reporting of clinical trials. The section also includes novel medicines derived from biotechnological processes and the use of pharmacogenetics/pharmacogenomics techniques to produce better targeted medicines. The Multidisciplinary guidelines consist of ICH medical terminology (MedDRA), the Common Technical Document (CTD), and the development of Electronic Standards for the Transfer of Regulatory Information (ESTRI).

In order to share regulatory information, ICH has formulated a standardized Medical Dictionary for Regulatory Activities (MedDRA). This is a general medical terminology that supports data analysis, communication, and data management. It is regularly updated and can be easily translated to other languages. Details are available on the sister website,

The Common Technical Document (CTD) contains the elements of quality, safety, and efficacy information in a common format. This makes the regulatory review processes simpler and allows for electronic submission. There are five modules in the CTD designed to harmonise submission of new drug applications (NDAs) in the electronic format. These have now evolved into the non proprietary Electronic Standards for the Transfer of Regulatory Information (ESTRI).

The reach of the ICH is not limited to the partner countries and training programs on regulatory and pharmacovigilance issues are conducted in many regions that have active pharmaceutical manufacturing facilities. Another initiative aimed at involving non ICH regions is the regulators forum that aims at involving various countries: Brazil, China, India and Russia, which have no formal agreement with the organization but are major clinical research hubs.

The publications link includes general documents and those related to MedDra and position papers. Surprisingly, it does not archive older publications which could be of help in understanding implementation of the guidelines.

Current advances in global pharmaceutical manufacturing involve harmonizing drug regulation. ICH guidelines reduce the expense of preparing registration dossiers and ensure improved quality, safety, and efficacy of marketed products. These initiatives are excellent value additions for the drug developers and regulatory authorities. Increased sharing of information and pharmacovigilance activities leads the consumer to repose more trust in the process. Public health in the developing countries also benefits by improved access especially to essential medicines.

The website of ICH and its content is essential reading for anyone who aims to gain an insight into regulations in drug development.

This article has been cited by
1 Development and validation of a robust analytical method to quantify both etoposide and prodigiosin in polymeric nanoparticles by reverse-phase high-performance liquid chromatography
M. M. Agwa,F. M. Elessawy,A. Hussein,M. A. El Demellawy,A. O. Elzoghby,M. H. Abd El-Salam,A. I. Eldiwany
Analytical Methods. 2018; 10(19): 2272
[Pubmed] | [DOI]
2 Surveillance of drugs that most frequently induce acute kidney injury: A pharmacovigilance approach
Keiko Hosohata,Ayaka Inada,Saki Oyama,Daisuke Furushima,Hiroshi Yamada,Kazunori Iwanaga
Journal of Clinical Pharmacy and Therapeutics. 2018;
[Pubmed] | [DOI]
3 Orthogonal Separations in Reversed-Phase Chromatography
Roopali Agrawal,Sateesh Belemkar,Chandrakant Bonde
Chromatographia. 2018; 81(4): 565
[Pubmed] | [DOI]
4 Adverse drug event profile associated with pregabalin among patients with and without cancer: analysis of a spontaneous reporting database
Eiji Kose
Journal of Clinical Pharmacy and Therapeutics. 2018;
[Pubmed] | [DOI]
5 Serum S100B Levels Can Predict Computed Tomography Findings in Paediatric Patients with Mild Head Injury
Fatos M. Kelmendi,Arsim A. Morina,Agon Y. Mekaj,Afrim Blyta,Ridvan Alimehmeti,Shefki Dragusha,Feti Ahmeti,Qamile Morina,Afrim Kotori
BioMed Research International. 2018; 2018: 1
[Pubmed] | [DOI]
6 Quantitative 1H-NMR Spectroscopy for Profiling Primary Metabolites in Mulberry Leaves
Qianqian Liang,Qiuying Wang,Yuan Wang,Ya-nan Wang,Jia Hao,Miaomiao Jiang
Molecules. 2018; 23(3): 554
[Pubmed] | [DOI]
7 Building Capability for Clinical Pharmacology Research in Sub-Saharan Africa
MM Gutierrez,G Pillai,S Felix,F Romero,KO Onyango,S Owusu-Agyei,KP Asante,KI Barnes,P Sinxadi,E Allen,S Abdulla,C Masimirembwa,M Munyoro,G Yimer,T Gebre-Mariam,J Spector,B Ogutu
Clinical Pharmacology & Therapeutics. 2017;
[Pubmed] | [DOI]
8 The Occurrence of Zearalenone in South Korean Feedstuffs between 2009 and 2016
Hansub Chang,Woori Kim,Ju-Hee Park,Dongho Kim,Choong-Ryeol Kim,Soohyun Chung,Chan Lee
Toxins. 2017; 9(7): 223
[Pubmed] | [DOI]
9 A Decrease of Incidence Cases of Fumonisins in South Korean Feedstuff between 2011 and 2016
Juhee Park,Hansub Chang,Seungran Hong,Dongho Kim,Soohyun Chung,Chan Lee
Toxins. 2017; 9(9): 286
[Pubmed] | [DOI]
10 Adherence reporting in clinical trials of type 2 Diabetes Metellius in the field of Traditional Chinese Medicine
Xing Dongmei,Zhang Junhua,Zhu Mingjun,Zhao Yu,Shang Hongcai
Journal of Traditional Chinese Medicine. 2017; 37(1): 140
[Pubmed] | [DOI]
11 TRIPS and disclosure of clinical information: An intellectual property perspective on data sharing
Gabriele Spina Aĺ
The Journal of World Intellectual Property. 2017;
[Pubmed] | [DOI]
12 Capillary electrophoresis with online stacking in combination with [email protected] reinforced hollow fiber solid-liquid phase microextraction for quantitative analysis of Capecitabine and its main metabolite 5-Fluorouracil in plasma samples isolated from cancer patients
Mehrdad Forough,Khalil Farhadi,Rahim Molaei,Hedayat Khalili,Ramin Shakeri,Asghar Zamani,Amir Abbas Matin
Journal of Chromatography B. 2017; 1040: 22
[Pubmed] | [DOI]
13 An Overview of Pharmaceutical Excipients: Safe or Not Safe?
Cátia G. Abrantes,Dinah Duarte,Catarina P. Reis
Journal of Pharmaceutical Sciences. 2016; 105(7): 2019
[Pubmed] | [DOI]
14 Reducing head computed tomography after mild traumatic brain injury: Screening value of clinical findings and S100B protein levels
Shadi Asadollahi,Kamran Heidari,Mehrdad Taghizadeh,Arash Mohammad Seidabadi,Morteza Jamshidian,Ali Vafaee,Mohammad Manoochehri,Ali Habibzade Shojaee,Hamid Reza Hatamabadi
Brain Injury. 2016; 30(2): 172
[Pubmed] | [DOI]


    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  In this article

 Article Access Statistics
    PDF Downloaded570    
    Comments [Add]    
    Cited by others 14    

Recommend this journal